Language:
English
繁體中文
Help
Login
Back
Switch To:
Labeled
|
MARC Mode
|
ISBD
Target validation in drug discovery
~
ScienceDirect (Online service)
Target validation in drug discovery
Record Type:
Language materials, printed : Monograph/item
Title/Author:
Target validation in drug discovery/ editors, Brian W. Metcalf and Susan Dillon.
other author:
Metcalf, Brian W.
Published:
Amsterdam ;Academic Press, : c2007.,
Description:
xii, 279 p. :ill. ; : 27 cm.;
Subject:
Drug development. -
Online resource:
An electronic book accessible through the World Wide Web; click for information
ISBN:
9780123693938
Target validation in drug discovery
Target validation in drug discovery
[electronic resource] /editors, Brian W. Metcalf and Susan Dillon. - Amsterdam ;Academic Press,c2007. - xii, 279 p. :ill. ;27 cm.
Includes bibliographical references and index.
Section Contents -- I. Pharmaceutical Biotechnology for Target Validation -- II. Target Validation for Biopharmaceutical Drug Discovery -- III. Validating Targets of Small Molecule Approaches.
This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin. Additional targets known as "second generation" drugs, which can be identified when disease pathways are validated by biologics, present new possible small molecule therapeutics and serve as the focus of the final section of the book.
Electronic reproduction.
Amsterdam :
Elsevier Science & Technology,
2007.
Mode of access: World Wide Web.
ISBN: 9780123693938
Source: 113098:113186Elsevier Science & Technologyhttp://www.sciencedirect.comSubjects--Topical Terms:
581824
Drug development.
Index Terms--Genre/Form:
554714
Electronic books.
LC Class. No.: RM301.63 / .T36 2007eb
Dewey Class. No.: 615/.19
National Library of Medicine Call No.: 2006 N-124
Target validation in drug discovery
LDR
:02227cam 2200337Ia 4500
001
680136
003
OCoLC
005
20110615082928.0
006
m d
007
cr cn|||||||||
008
111108s2007 enka ob 001 0 eng d
020
$a
9780123693938
020
$a
0123693934
029
1
$a
NZ1
$b
11778208
035
$a
(OCoLC)162130366
035
$a
ocn162130366
037
$a
113098:113186
$b
Elsevier Science & Technology
$n
http://www.sciencedirect.com
040
$a
OPELS
$c
OPELS
$d
OCLCG
049
$a
TEFA
050
1 4
$a
RM301.63
$b
.T36 2007eb
060
1 4
$a
2006 N-124
060
1 4
$a
QV 744
$b
T185 2007
082
0 4
$a
615/.19
$2
22
245
0 0
$a
Target validation in drug discovery
$h
[electronic resource] /
$c
editors, Brian W. Metcalf and Susan Dillon.
260
$a
Amsterdam ;
$a
Boston :
$b
Academic Press,
$c
c2007.
300
$a
xii, 279 p. :
$b
ill. ;
$c
27 cm.
504
$a
Includes bibliographical references and index.
505
0
$a
Section Contents -- I. Pharmaceutical Biotechnology for Target Validation -- II. Target Validation for Biopharmaceutical Drug Discovery -- III. Validating Targets of Small Molecule Approaches.
520
$a
This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin. Additional targets known as "second generation" drugs, which can be identified when disease pathways are validated by biologics, present new possible small molecule therapeutics and serve as the focus of the final section of the book.
533
$a
Electronic reproduction.
$b
Amsterdam :
$c
Elsevier Science & Technology,
$d
2007.
$n
Mode of access: World Wide Web.
$n
System requirements: Web browser.
$n
Title from title screen (viewed on July 25, 2007).
$n
Access may be restricted to users at subscribing institutions.
650
0
$a
Drug development.
$3
581824
650
0
$a
Drugs
$x
Testing.
$3
581825
650
0
$a
High throughput screening (Drug development)
$3
582128
650
1 2
$a
Drug Design.
$3
557397
650
2 2
$a
Drug Delivery Systems.
$3
581038
650
2 2
$a
Technology, Pharmaceutical.
$3
582287
650
6
$a
M�edicaments
$x
D�eveloppement.
$3
791583
650
6
$a
M�edicaments
$x
Essais cliniques.
$3
791584
650
6
$a
Criblage �a haut d�ebit (D�eveloppement des m�edicaments)
$3
791585
655
7
$a
Electronic books.
$2
local
$3
554714
700
1
$a
Metcalf, Brian W.
$3
791581
700
1
$a
Dillon, Susan,
$d
1952-
$3
791582
710
2
$a
ScienceDirect (Online service)
$3
636041
856
4 0
$3
ScienceDirect
$u
http://www.sciencedirect.com/science/book/9780123693938
$z
An electronic book accessible through the World Wide Web; click for information
994
$a
C0
$b
TEF
based on 0 review(s)
Multimedia
Reviews
Add a review
and share your thoughts with other readers
Export
pickup library
Processing
...
Change password
Login